Anavex Life Sciences
AVXL
139 hedge funds and large institutions have $249M invested in Anavex Life Sciences in 2022 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 61 increasing their positions, 28 reducing their positions, and 24 closing their positions.
118% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 28
3.34% more ownership
Funds ownership: 31.26% → 34.61% (+3.3%)
1% less capital invested
Capital invested by funds: $251M → $249M (-$2.65M)
5% less funds holding
Funds holding: 147 → 139 (-8)
25% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 24
39% less call options, than puts
Call options by funds: $17.1M | Put options by funds: $28M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$15.5M |
| 2 |
Millennium Management
New York
|
+$6.73M |
| 3 |
Goldman Sachs
New York
|
+$4.2M |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$2.85M |
| 5 |
BlackRock
New York
|
+$2.82M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$3.79M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$2.94M |
| 3 |
D.E. Shaw & Co
New York
|
-$2.76M |
| 4 |
Barclays
London,
United Kingdom
|
-$1.92M |
| 5 |
PC
Pier Capital
Stamford,
Connecticut
|
-$1.11M |
AVXL Hedge Fund Activity: Q4 2022 in Review
139 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Anavex Life Sciences (AVXL) for Q4 2022, worth a combined $249M — down 1.1% from $251M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of AVXL and 18 opened new positions — a net loss of 6 holders — while 28 trimmed existing stakes and 61 added.
The largest buyer was State Street, adding an estimated $15.5M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $3.79M sold.
- 139 institutional investors held Anavex Life Sciences (AVXL) as of Q4 2022, down from 147 in Q3 2022.
- Funds reported $249M of Anavex Life Sciences stock for Q4 2022, down 1.1% quarter-over-quarter.
- 18 funds opened new Anavex Life Sciences positions in Q4 2022 and 24 closed out, a net change of -6 holders.
- The largest Anavex Life Sciences buyer in Q4 2022 was State Street, an estimated $15.5M added.
- The largest Anavex Life Sciences seller in Q4 2022 was Renaissance Technologies, an estimated $3.79M sold.
Based on aggregated 13F filings for Q4 2022.